With a strong background in technology and healthcare investments, the fund manager has successfully executed over 50 deals across North America and Europe. Emphasizing a data-driven approach, they have cultivated a diverse portfolio that includes several notable exits in the biotech sector. Their investment strategy focuses on early to growth-stage companies, leveraging extensive operational expertise to drive value creation. Recognized for a thematic investment style, they strategically target disruptive innovations that address pressing market needs.